Ost-müük Agenus - AGEN CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.0162 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | 1.4769 |
| Avatud* | 1.4669 |
| Aastane muutus* | -44.65% |
| Päeva ulatus* | 1.437 - 1.4968 |
| 52 nädala ulatus | 1.25-3.37 |
| Keskmine maht (10 päeva) | 7.50M |
| Keskmine maht (3 kuud) | 96.68M |
| Turukapitalisatsioon | 492.12M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 332.51M |
| Tulu | 98.03M |
| EPS | -0.78 |
| Dividendid (% kasumist) | N/A |
| Beeta | 1.50 |
| Järgmine tuluaruande kuupäev | May 8, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Mar 24, 2023 | 1.4869 | 0.0300 | 2.06% | 1.4569 | 1.5068 | 1.4270 |
| Mar 23, 2023 | 1.4769 | -0.0498 | -3.26% | 1.5267 | 1.5467 | 1.4469 |
| Mar 22, 2023 | 1.4968 | -0.1298 | -7.98% | 1.6266 | 1.6266 | 1.4968 |
| Mar 21, 2023 | 1.6266 | 0.0100 | 0.62% | 1.6166 | 1.6864 | 1.6166 |
| Mar 20, 2023 | 1.6266 | -0.0998 | -5.78% | 1.7264 | 1.7264 | 1.6166 |
| Mar 17, 2023 | 1.6864 | -0.1098 | -6.11% | 1.7962 | 1.8162 | 1.6765 |
| Mar 16, 2023 | 1.8262 | -0.0598 | -3.17% | 1.8860 | 1.9958 | 1.8162 |
| Mar 15, 2023 | 1.8960 | 0.1397 | 7.95% | 1.7563 | 1.9260 | 1.7164 |
| Mar 14, 2023 | 1.7862 | -0.0799 | -4.28% | 1.8661 | 1.8960 | 1.6565 |
| Mar 13, 2023 | 1.7064 | 0.2395 | 16.33% | 1.4669 | 1.7264 | 1.4669 |
| Mar 10, 2023 | 1.4968 | -0.1397 | -8.54% | 1.6365 | 1.6365 | 1.4070 |
| Mar 9, 2023 | 1.6366 | -0.0898 | -5.20% | 1.7264 | 1.7563 | 1.6066 |
| Mar 8, 2023 | 1.6964 | -0.0599 | -3.41% | 1.7563 | 1.7763 | 1.6765 |
| Mar 7, 2023 | 1.7363 | -0.0998 | -5.44% | 1.8361 | 1.8361 | 1.7164 |
| Mar 6, 2023 | 1.8162 | -0.1297 | -6.67% | 1.9459 | 1.9559 | 1.8162 |
| Mar 3, 2023 | 1.9359 | -0.0200 | -1.02% | 1.9559 | 1.9759 | 1.8960 |
| Mar 2, 2023 | 1.9260 | 0.0100 | 0.52% | 1.9160 | 1.9559 | 1.8960 |
| Mar 1, 2023 | 1.9359 | -0.1098 | -5.37% | 2.0457 | 2.0657 | 1.8960 |
| Feb 28, 2023 | 2.0557 | 0.0599 | 3.00% | 1.9958 | 2.0856 | 1.9759 |
| Feb 27, 2023 | 1.9559 | -0.0599 | -2.97% | 2.0158 | 2.0158 | 1.9459 |
Agenus Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kogutulu | 295.665 | 88.17 | 150.048 | 36.7836 | 42.8771 |
| Tulu | 295.665 | 88.17 | 150.048 | 36.7836 | 42.8771 |
| Kogu tegevuskulu | 263.721 | 208.125 | 220.185 | 171.372 | 146.678 |
| Müük/Üldine/admin kulud, kokku | 76.359 | 59.218 | 46.041 | 37.3397 | 33.7412 |
| Uuringud ja arendus | 178.608 | 142.617 | 168.339 | 124.6 | 116.125 |
| Other Operating Expenses, Total | 5.805 | -1.335 | -3.188 | ||
| Tulud majandustegevusest | 31.944 | -119.955 | -70.137 | -134.588 | -103.801 |
| Intressitulud (kulu), muud tulud, neto | -65.719 | -61.078 | -41.451 | -25.2726 | -18.8685 |
| Muud, neto | 5.051 | -1.858 | 0.028 | -2.18328 | 1.9774 |
| Netotulu enne makse | -28.724 | -182.891 | -111.56 | -162.044 | -120.692 |
| Netotulu pärast makse | -28.724 | -182.891 | -111.56 | -162.044 | -120.692 |
| Netotulu enne erikulusid | -23.926 | -180.914 | -107.657 | -159.692 | -120.692 |
| Netotulu | -23.926 | -180.914 | -107.657 | -159.692 | -120.692 |
| Total Adjustments to Net Income | -0.211 | -0.209 | -0.208 | -0.20684 | -0.20554 |
| Arvestatav tulu, v a erikulud | -24.137 | -181.123 | -107.865 | -159.899 | -120.898 |
| Arvestatav tulu, koos erikuludega | -24.137 | -181.123 | -107.865 | -159.899 | -120.898 |
| Jaotamisele kuuluv netotulu | -24.137 | -181.123 | -107.865 | -159.899 | -120.898 |
| Keskmine jaotamisele kuuluv aktsia kohta | 228.919 | 172.504 | 134.982 | 110.772 | 98.4154 |
| Jaotatav EPS, v a erakorralised kulud | -0.10544 | -1.04996 | -0.79911 | -1.44349 | -1.22845 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Jaotamisele kuuluv normaal-EPS | -0.13251 | -1.0342 | -0.79911 | -1.3463 | -1.22845 |
| Erakorralised kulud kokku | 0 | 0 | |||
| Ootamatud kulutused (tulu) | -6.197 | 2.72 | 0 | 10.7666 | |
| Vähemuse intress | 4.798 | 1.977 | 3.903 | 2.3519 | |
| Kulud, Kokku | 3.47 | 2.349 | |||
| Brutokasum | 292.195 | 85.821 | |||
| Intressikulu (tulu) - neto majandustegevusest | 11.481 | 1.221 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kogutulu | 25.941 | 20.261 | 252.954 | 10.73 | 11.719 |
| Tulu | 25.941 | 20.261 | 252.954 | 10.73 | 11.719 |
| Kulud, Kokku | 0.543 | 0.881 | 0.817 | 0.667 | 1.105 |
| Brutokasum | 25.398 | 19.38 | 252.137 | 10.063 | 10.614 |
| Kogu tegevuskulu | 61.402 | 74.288 | 59.217 | 77.125 | 53.09 |
| Müük/Üldine/admin kulud, kokku | 18.953 | 21.971 | 21.385 | 16.65 | 16.352 |
| Uuringud ja arendus | 42.442 | 53.486 | 42.937 | 45.508 | 36.677 |
| Intressikulu (tulu) - neto majandustegevusest | -0.536 | -2.05 | 0.275 | 14.3 | -1.044 |
| Tulud majandustegevusest | -35.461 | -54.027 | 193.737 | -66.395 | -41.371 |
| Intressitulud (kulu), muud tulud, neto | -15.199 | -16.572 | -16.581 | -16.676 | -15.89 |
| Muud, neto | 0.056 | 2.992 | 0.121 | -0.92 | 2.858 |
| Netotulu enne makse | -50.604 | -67.607 | 177.277 | -83.991 | -54.403 |
| Netotulu pärast makse | -50.604 | -67.607 | 177.277 | -83.991 | -54.403 |
| Vähemuse intress | 2.279 | 2.096 | 1.275 | 0.701 | 0.726 |
| Netotulu enne erikulusid | -48.325 | -65.511 | 178.552 | -83.29 | -53.677 |
| Netotulu | -48.325 | -65.511 | 178.552 | -83.29 | -53.677 |
| Total Adjustments to Net Income | -0.053 | -0.053 | -0.053 | -0.053 | -0.053 |
| Arvestatav tulu, v a erikulud | -48.378 | -65.564 | 178.499 | -83.343 | -53.73 |
| Arvestatav tulu, koos erikuludega | -48.378 | -65.564 | 178.499 | -83.343 | -53.73 |
| Jaotamisele kuuluv netotulu | -48.378 | -65.564 | 178.499 | -83.343 | -53.73 |
| Keskmine jaotamisele kuuluv aktsia kohta | 258.31 | 256.645 | 246.726 | 222.906 | 200.331 |
| Jaotatav EPS, v a erakorralised kulud | -0.18729 | -0.25547 | 0.72347 | -0.37389 | -0.26821 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.18729 | -0.25547 | 0.69835 | -0.37389 | -0.26821 |
| Ootamatud kulutused (tulu) | 0 | -6.197 | 0 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 331.974 | 113.783 | 86.536 | 74.8077 | 73.5536 |
| Raha ja lühiajalised investeeringud | 306.923 | 99.871 | 61.808 | 53.0535 | 60.1866 |
| Raha ja ekvivalendid | 291.931 | 99.871 | 61.808 | 53.0535 | 60.1866 |
| Lühiajalised investeeringud | 14.992 | 0 | |||
| Laekumata arved, neto | 1.518 | 1.157 | 16.293 | 0.93814 | 1.13449 |
| Accounts Receivable - Trade, Net | 1.518 | 1.157 | 16.293 | 0.93814 | 1.13449 |
| Total Inventory | 0 | 0.05549 | 0.07949 | ||
| Prepaid Expenses | 20.362 | 10.746 | 7.42 | 19.2648 | 11.071 |
| Other Current Assets, Total | 3.171 | 2.009 | 1.015 | 1.49572 | 1.08199 |
| Total Assets | 465.958 | 214.514 | 155.335 | 136.401 | 138.402 |
| Property/Plant/Equipment, Total - Net | 91.083 | 60.27 | 33.69 | 25.1156 | 26.1786 |
| Property/Plant/Equipment, Total - Gross | 141.622 | 107.471 | 76.551 | 63.1836 | 60.2076 |
| Accumulated Depreciation, Total | -50.539 | -47.201 | -42.861 | -38.068 | -34.029 |
| Goodwill, Net | 24.876 | 25.452 | 23.188 | 22.9249 | 23.0488 |
| Intangibles, Net | 8.488 | 10.886 | 10.504 | 12.3382 | 14.4066 |
| Other Long Term Assets, Total | 9.537 | 4.123 | 1.417 | 1.21439 | 1.21439 |
| Total Current Liabilities | 156.943 | 129.884 | 122.209 | 68.0622 | 56.4381 |
| Accounts Payable | 30.486 | 17.015 | 13.564 | 13.6239 | 8.08699 |
| Accrued Expenses | 44.718 | 31.007 | 32.679 | 24.5513 | 21.5695 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1.063 | 1.579 | 0.794 | 0.14606 | 20.6397 |
| Other Current Liabilities, Total | 80.676 | 80.283 | 75.172 | 29.7409 | 6.14195 |
| Total Liabilities | 431.518 | 391.269 | 353.774 | 268.989 | 214.218 |
| Total Long Term Debt | 13.141 | 18.945 | 13.38 | 13.2115 | 142.385 |
| Long Term Debt | 12.823 | 18.879 | 13.38 | 13.2115 | 142.385 |
| Other Liabilities, Total | 247.965 | 250.266 | 224.166 | 189.794 | 15.3947 |
| Total Equity | 34.44 | -176.755 | -198.439 | -132.588 | -75.8158 |
| Redeemable Preferred Stock | 0 | 0 | 32.8321 | 32.6252 | |
| Preferred Stock - Non Redeemable, Net | 0 | 26.917 | 26.917 | 7.04734 | -32.6249 |
| Common Stock | 2.569 | 1.961 | 1.378 | 1.19996 | 1.01706 |
| Additional Paid-In Capital | 1520.21 | 1257.5 | 1059.58 | 1005.18 | 951.812 |
| Retained Earnings (Accumulated Deficit) | -1489.83 | -1465.91 | -1284.99 | -1177.31 | -1026.48 |
| Other Equity, Total | 1.492 | 2.772 | -1.324 | -1.53937 | -2.16935 |
| Total Liabilities & Shareholders’ Equity | 465.958 | 214.514 | 155.335 | 136.401 | 138.402 |
| Total Common Shares Outstanding | 256.898 | 196.091 | 137.818 | 119.996 | 101.706 |
| Total Preferred Shares Outstanding | 0.03162 | 0.04408 | 0.04408 | 0.05008 | 0.03162 |
| Minority Interest | 13.469 | -7.826 | -5.981 | -2.0783 | |
| Capital Lease Obligations | 0.318 | 0.066 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 290.483 | 331.974 | 308.401 | 92.854 | 135.663 |
| Raha ja lühiajalised investeeringud | 262.687 | 306.923 | 261.528 | 73.543 | 119.366 |
| Raha ja ekvivalendid | 247.709 | 291.931 | 256.529 | 73.543 | 119.366 |
| Laekumata arved, neto | 1.286 | 1.518 | 21.773 | 1.436 | 2.173 |
| Accounts Receivable - Trade, Net | 1.286 | 1.518 | 21.773 | 1.436 | 2.173 |
| Prepaid Expenses | 21.73 | 20.362 | 18.342 | 13.628 | 10.678 |
| Other Current Assets, Total | 4.78 | 3.171 | 6.758 | 4.247 | 3.446 |
| Total Assets | 441.305 | 465.958 | 437.639 | 192.299 | 234.915 |
| Property/Plant/Equipment, Total - Net | 105.919 | 91.083 | 81.525 | 60.992 | 60.734 |
| Property/Plant/Equipment, Total - Gross | 127.11 | 110.568 | 99.712 | 78.238 | 75.503 |
| Accumulated Depreciation, Total | -51.507 | -50.539 | -49.433 | -49.528 | -48.354 |
| Goodwill, Net | 24.617 | 24.876 | 24.528 | 24.706 | 24.334 |
| Intangibles, Net | 7.753 | 8.488 | 8.993 | 9.594 | 9.994 |
| Other Long Term Assets, Total | 12.533 | 9.537 | 14.192 | 4.153 | 4.19 |
| Total Current Liabilities | 163.062 | 156.943 | 150.131 | 168.754 | 138.374 |
| Accounts Payable | 34.544 | 30.486 | 25.118 | 19.164 | 19.477 |
| Accrued Expenses | 35.318 | 44.718 | 34.323 | 32.461 | 33.106 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 14.181 | 0.728 | 0.542 | 0.838 | 1.463 |
| Other Current Liabilities, Total | 79.019 | 81.011 | 90.148 | 116.291 | 84.328 |
| Total Liabilities | 425.587 | 431.518 | 395.785 | 421.142 | 401.979 |
| Total Long Term Debt | 0 | 12.823 | 12.786 | 18.947 | 18.913 |
| Long Term Debt | 0 | 12.823 | 12.786 | 18.947 | 18.913 |
| Minority Interest | 11.932 | 13.469 | -6.301 | -8.634 | -8.289 |
| Other Liabilities, Total | 250.593 | 248.283 | 239.169 | 242.075 | 252.981 |
| Total Equity | 15.718 | 34.44 | 41.854 | -228.843 | -167.064 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 18.275 | 22.596 | |
| Common Stock | 2.667 | 2.569 | 2.475 | 2.253 | 2.179 |
| Additional Paid-In Capital | 1550.24 | 1520.21 | 1463.52 | 1353.24 | 1328.75 |
| Retained Earnings (Accumulated Deficit) | -1538.16 | -1489.83 | -1424.32 | -1602.87 | -1519.58 |
| Other Equity, Total | 0.97 | 1.492 | 0.177 | 0.26 | -1.002 |
| Total Liabilities & Shareholders’ Equity | 441.305 | 465.958 | 437.639 | 192.299 | 234.915 |
| Total Common Shares Outstanding | 266.74 | 256.898 | 247.512 | 225.263 | 217.862 |
| Total Preferred Shares Outstanding | 0.03162 | 0.03162 | 0.04408 | 0.04008 | 0.04208 |
| Lühiajalised investeeringud | 14.978 | 14.992 | 4.999 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -28.724 | -182.891 | -111.56 | -162.044 | -120.692 |
| Raha majandustegevusest | 10.145 | -139.096 | -18.682 | -131.095 | -94.2251 |
| Raha majandustegevusest | 6.788 | 7.179 | 6.662 | 6.288 | 6.0063 |
| Deferred Taxes | 0 | ||||
| Mittelikviidsed varad | 41.824 | 27.662 | 27.532 | 24.4914 | 26.94 |
| Makstud intressid | 1.152 | 1.176 | 1.224 | 1.17109 | 1.12 |
| Muutused tööjõus | -9.743 | 8.954 | 58.684 | 0.17005 | -6.47897 |
| Tulu investeeringutelt | -43.15 | -4.441 | -4.657 | -3.59092 | 2.0636 |
| Kapitalikulutused | -33.814 | -3.466 | -4.657 | -3.59711 | -3.12036 |
| Muud rahavood investeeringutelt, kokku | -9.336 | -0.975 | 0 | 0.00619 | 5.18395 |
| Rahavood investeeringutelt | 225.264 | 183.855 | 31.323 | 128.285 | 80.5382 |
| Rahavoogudesse investeerimine | -1.542 | 0 | 204.384 | -0.15 | |
| Aktsiate emiteerimine (tagasiost), neto | 228.123 | 180.89 | 31.643 | 86.0315 | 66.019 |
| Laenu väljastamine (kustutamine), neto | -1.317 | 2.965 | -0.32 | -162.131 | 14.6693 |
| Muutused valuutakursside kõikumisest | -0.164 | 0.379 | 0.77 | -0.73257 | 0.36192 |
| Rahaline kogumuutus | 192.095 | 40.697 | 8.754 | -7.13309 | -11.2614 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -50.604 | -28.724 | 38.883 | -138.394 | -54.403 |
| Cash From Operating Activities | -52.391 | 10.145 | 33.072 | -98.301 | -42.744 |
| Cash From Operating Activities | 1.66 | 6.788 | 5.133 | 3.452 | 1.729 |
| Non-Cash Items | 1.775 | 41.824 | 41.188 | 38.532 | 10.084 |
| Cash Interest Paid | 0.279 | 1.152 | 0.862 | 0.577 | 0.278 |
| Changes in Working Capital | -5.222 | -9.743 | -52.132 | -1.891 | -0.154 |
| Cash From Investing Activities | -7.533 | -43.15 | -29.851 | -2.466 | -0.196 |
| Capital Expenditures | -4.544 | -33.814 | -24.852 | -2.466 | -0.196 |
| Cash From Financing Activities | 16.038 | 225.264 | 153.659 | 74.754 | 62.962 |
| Issuance (Retirement) of Stock, Net | 16.17 | 228.123 | 156.266 | 75.603 | 63.385 |
| Issuance (Retirement) of Debt, Net | -0.132 | -1.317 | -1.065 | -0.849 | -0.423 |
| Foreign Exchange Effects | -0.336 | -0.164 | -0.187 | -0.28 | -0.492 |
| Net Change in Cash | -44.222 | 192.095 | 156.693 | -26.293 | 19.53 |
| Other Investing Cash Flow Items, Total | -2.989 | -9.336 | -4.999 | 0 | |
| Financing Cash Flow Items | -1.542 | -1.542 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Deep Track Capital LP | Hedge Fund | 8.12 | 27000000 | 675000 | 2022-12-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.2865 | 24228736 | 1411226 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 6.7978 | 22603650 | 2277707 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.7364 | 19074337 | 1773871 | 2022-12-31 | LOW |
| The Invus Group, LLC | Investment Advisor | 4.7009 | 15631235 | 15631235 | 2023-01-23 | MED |
| Invus Public Equities Advisors, LLC | Investment Advisor | 4.3607 | 14500000 | 10500000 | 2022-12-31 | LOW |
| Incyte Corp | Corporation | 3.63 | 12070195 | -1992032 | 2021-12-31 | |
| Gilead Sciences Inc | Corporation | 3.3416 | 11111111 | 0 | 2021-12-31 | LOW |
| Point72 Asset Management, L.P. | Hedge Fund | 2.6836 | 8923300 | 551100 | 2022-12-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5787 | 5249357 | 432108 | 2022-12-31 | LOW |
| Oracle Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.4709 | 4890872 | 399612 | 2022-12-31 | MED |
| Renaissance Technologies LLC | Hedge Fund | 1.1681 | 3884115 | -1246300 | 2022-12-31 | HIGH |
| Nuveen LLC | Pension Fund | 0.8822 | 2933363 | 4739 | 2022-12-31 | LOW |
| Sofinnova Investments, Inc | Venture Capital | 0.8704 | 2894057 | 456592 | 2022-12-31 | MED |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7128 | 2370269 | 128490 | 2022-12-31 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 0.6327 | 2103882 | 198327 | 2022-12-31 | LOW |
| SELECTRA Management Company S.A. | Investment Advisor | 0.6316 | 2100000 | 1520000 | 2022-06-30 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.6118 | 2034301 | 3157 | 2022-12-31 | LOW |
| Armen (Garo H.) | Individual Investor | 0.5877 | 1954139 | 241383 | 2023-01-05 | LOW |
| Goldman Sachs & Company, Inc. | Research Firm | 0.5403 | 1796706 | 694122 | 2022-12-31 | MED |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Agenus Company profile
Ettevõttest Agenus
Agenus Inc. on kliinilises staadiumis olev immunonkoloogia (I-O) ettevõte. Ettevõte pakub vähktõve vastu võitlemiseks immuunsüsteemi kontrollpunkti antikehi, adoptiivseid rakuteraapiaid ja neoantigeenseid vähivaktsiine. Tema I-O varade hulka kuuluvad antikehapõhised ravimid, mono- ja kahespetsiifilised antikehad, rakuteraapia, vaktsiinid ja adjuvandid. Tema antikehakandidaadid on balstilimab (PD-1-vastane antikeha) ja zalifrelimab (CTLA-4-vastane antikeha), mis on 2. faasi uuringutes nii monoteraapiana (balstilimab) kui ka kombinatsiooniteraapiana (balstilimab/zalifrelimab) emakakaelavähiga patsientide raviks. Kliinilises staadiumis olevate ravimite portfelli kuuluvad ka botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 ja AGENT 797. Ta arendab personaliseeritud vaktsiine, nimelt Prophage ja AutoSynVax, ning valmisvaktsiine PhosphoSynVax, mis sisaldab kuumalöögivalke, et toimetada neoantigeene õigetele immuunrakkudele, et aktiveerida vähivastane immuunvastus.
| Industry: | Biotechnology & Medical Research (NEC) |
3 Forbes Rd
LEXINGTON
MASSACHUSETTS 02421-7305
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com